FeesSafety
Pluang+

Rex Drone ETF (DRNZ) rated strong buy for growth amid booming US drone and defense sectors.

08 Nov 2026, 21:05 WIB
Seeking Alpha
View Source
Bullish
Rex Drone ETF (DRNZ) rated strong buy for growth amid booming US drone and defense sectors.

The Rex Drone ETF (DRNZ) offers focused exposure to the growing drone and defense industry, driven by increased U.S. defense spending and protection from Chinese competition. The ETF is recommended as a strong buy for investors who can tolerate volatility, with potential income from cash-secured puts. Drone adoption is expanding in logistics, agriculture, infrastructure, and public safety, signaling robust growth prospects for the sector.

The Rex Drone ETF (DRNZ) is highlighted in recent news as a way to invest in drone industry growth. For readers following Industrials-sector stocks, here is Pluang's market snapshot as of Nov 09, 2026 02:21 WIB: Of 135 priced stocks, 81 rose and 53 fell today. Notable movers include FTAI Aviation Ltd at USD 180.27 with a 1-day change of +10.97% and a typical hold time of 27 days, Geo Group Inc REIT at USD 27.80 up +10.45% with a typical hold time of 12 days, and Planet Labs at USD 12.55 up +10.38% with a typical hold time of 11 days.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
4 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
4 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
4 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
4 hours ago
Bitcoin Cash drops 4.5%, deepening weekly losses over 13% as Bitcoin holds steady near $75,800

Bitcoin Cash drops 4.5%, deepening weekly losses over 13% as Bitcoin holds steady near $75,800

Bitcoin Cash (BCH) fell about 4.5% on November 8, extending its weekly losses beyond 13%, while Bitcoin remained stable near $75,800. BCH's price dropped below key support levels around $250 and tested $244, signaling weaker demand compared to Bitcoi...

Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App